Prolistem® at the ESHRE 41th – Paris

We are proud to have participated in the 41st Annual ESHRE Conference in Paris, a premier international event where the global reproductive medicine community gathers to exchange knowledge, ideas, and innovation.

This year’s conference marked an important milestone for Prolistem. As awareness continues to grow, we were honored to welcome doctors, researchers, and fertility specialists from around the world to our booth. Many of them were already familiar with Prolistem’s unique approach to non-obstructive azoospermia (NOA), and several shared firsthand experiences and success stories from their own clinics.

The growing interest in Prolistem reflects the increasing demand for non-invasive, science-based solutions for male infertility. Built on a deep understanding of testicular biology and supported by years of preclinical and clinical use, Prolistem’s mechanism—based on temporary testosterone modulation—continues to generate discussion and curiosity among experts seeking new options for their patients.

While Prolistem has not yet been incorporated into mainstream treatment guidelines, its reputation is spreading rapidly—particularly in regions where sperm donation is not an option due to cultural or religious reasons. In countries across the Middle East, Europe, and Asia, Prolistem is becoming a recognized name among fertility professionals seeking to improve outcomes in difficult NOA cases.

Our presence at ESHRE 2025 was more than just an exhibition—it was a powerful reminder of how far we’ve come as a small, independent team dedicated to transforming male fertility care. We are grateful for the engagement, the encouragement, and the ongoing support from the medical community.

We return from Paris with renewed energy and inspiration, committed to continuing our mission: to bring hope, clarity, and scientifically grounded solutions to men and couples around the world facing infertility.